Abrus Precatorius Seed Aconitum Napellus Allylthio

證據等級: L5

預測適應症: 0 個

Multi-Ingredient Homeopathic Combination Formula: No Repurposing Candidates Identified

One-Sentence Summary

This Evidence Pack describes a 51-ingredient multi-component formula whose individual constituents span plant extracts, minerals, animal venoms, and food-derived substances — consistent with a homeopathic combination product. The TxGNN model generated no predicted indications for this entry, likely because the compound could not be resolved to a single DrugBank or knowledge-graph node. As a result, no repurposing evidence, clinical trial links, or literature associations can be presented at this time.

Quick Overview

Item	Content
Original Indication	Not established — no regulatory approvals on record
Predicted New Indication	None — TxGNN returned no candidates
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only) — actually below L5; no prediction was generated
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This entry is registered under a single candidate ID (TW-UNKNOWN-multi) but contains 51 distinct active ingredients, ranging from botanical extracts (Aconitum napellus, Glycyrrhiza glabra, Garlic) to mineral compounds (Arsenic trioxide, Sulfur, Phosphorus), animal-derived substances (Lachesis muta venom, Sepia officinalis juice), and common food components (Lactose, Sucrose, Saccharin).

This ingredient profile is characteristic of a homeopathic combination product, where each constituent is included at highly diluted potency rather than as a pharmacologically active dose. Because TxGNN’s knowledge graph maps single-entity drugs (identified by a DrugBank ID) to disease nodes, a multi-ingredient entry without a unified DrugBank identifier cannot be processed by the prediction pipeline. No DrugBank ID was resolved, and accordingly no repurposing candidates were output.

A secondary concern is that several individual ingredients carry significant standalone pharmacological profiles — most notably arsenic trioxide (an approved antineoplastic for acute promyelocytic leukemia) and caffeine. However, within a homeopathic dilution context these are not equivalent to their therapeutic doses, and analyzing them individually as repurposing candidates would require separate, single-drug Evidence Pack submissions.

Conclusion and Next Steps

Decision: Hold

Rationale: The current Evidence Pack cannot support a repurposing evaluation because (1) the entry is a multi-ingredient mixture that cannot be matched to a single knowledge-graph node, (2) TxGNN returned zero predicted indications, and (3) no regulatory approval, mechanism of action data, or safety information is available.

To proceed, the following is needed:

Decompose the formula: If the intent is to evaluate a specific pharmacologically active ingredient (e.g., arsenic trioxide), submit a separate single-drug Evidence Pack for that ingredient with its own DrugBank ID.
Clarify product identity: Confirm whether this is a registered homeopathic product, an investigational formulation, or a data pipeline error (e.g., multiple drugs concatenated into a single INN field).
Resolve DrugBank ID: Without a valid DrugBank ID, TxGNN prediction, MOA analysis, and DDI screening cannot be performed.
Obtain regulatory status: If the product exists as a finished dosage form in any jurisdiction, retrieve the registration number and package insert to establish original indication and safety profile.
Resubmit as individual ingredients: For a systematic repurposing analysis, each clinically relevant component should be evaluated separately through the standard pipeline.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.